EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4 + EBP11-F1 + EBP11-F5
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoparathyroidism
Conditions
Hypoparathyroidism, Osteoporosis, Fractures, Bone, Other Disease
Trial Timeline
May 11, 2023 → Feb 8, 2026
NCT ID
NCT05965167About EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4 + EBP11-F1 + EBP11-F5
EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4 + EBP11-F1 + EBP11-F5 is a phase 1 stage product being developed by Entera Bio for Hypoparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT05965167. Target conditions include Hypoparathyroidism, Osteoporosis, Fractures, Bone.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05965167 | Phase 1 | Completed |
Competing Products
9 competing products in Hypoparathyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 2109 | MBX Biosciences | Phase 2 | 47 |
| 400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection | MBX Biosciences | Phase 2 | 47 |
| PCO371 + Placebo | Chugai Pharmaceutical | Phase 1 | 33 |
| recombinant human somatotropin | Eli Lilly | Pre-clinical | 23 |
| Palopegteriparatide | Ascendis Pharma | Pre-clinical | 20 |
| Palopegteriparatide (TransCon PTH) | Ascendis Pharma | Pre-clinical | 20 |
| Palopegteriparatide | Ascendis Pharma | Pre-clinical | 20 |
| EnteraBio's Oral Parathyroid Hormone (1-34) | Entera Bio | Phase 2 | 44 |
| EB612 (EBP05) + NATPARA/NATPAR | Entera Bio | Phase 2 | 44 |